MedTrace Logo

LXRA Gene Polymorphisms and Response to Fenofibrate

NCT00644592 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2012-06-01

Study results available
· View outcomes & findings →

Summary

This is a research study of how a cholesterol medication known as fenofibrate works differently in people with different genetic backgrounds. "Genetics" refers to certain things that are passed to a person by their parents, such as eye color or hair color. Genetic differences lead to people having different eye and hair color. There are also genetic differences in a protein called liver X receptor-alpha (LXRA), which may be important in predicting the response to fenofibrate.

Conditions

  • Healthy

Interventions

DRUG

Fenofibrate capsule daily for 4 weeks

Placebo capsule daily for 4 weeks

DRUG

Fenofibrate

160 mg/day orally for 4 weeks

Sponsors & Collaborators

  • American College of Clinical Pharmacy

    collaborator OTHER

  • University of Florida

    lead OTHER

Principal Investigators

  • Issam Zineh, PharmD · University of Florida College of Pharmacy, Department of Pharmacy Practice, Center for Pharmacogenomics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00644592 on ClinicalTrials.gov